Houman Ashrafian, MD, PhD

Houman Ashrafian, MD, PhD, is a Managing Partner at SV Health Investors and co-founded TRexBio in 2018.

Alongside TRexBio, he has founded five other SV companies: Alchemab, Catamaran Bio, Enara Bio, Mestag and Sitryx. Dr. Ashrafian serves on the Dementia Discovery Fund (DDF) Investment Committee and on the boards of Therini and Imbria.

Previously, Dr. Ashrafian co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Outside of SV, following completion of his cardiology training, Dr. Ashrafian was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and head of Experimental Therapeutics at the University of Oxford. Additionally, he is Co-founder and Chairman of Weatherden, a boutique clinical development company.